By: Natalie Johnson
The promise of AI in biotech is undeniable, yet many organizations are discovering that technical innovation alone does not translate into commercial success. While investment in AI commercialization accelerates, a persistent gap remains between data-driven insights and tangible revenue outcomes. Data scientists focus on model accuracy, while commercial teams are measured on pipeline velocity and closed deals. This misalignment slows scientific alignment, delays deal acceleration, and limits the conversion of breakthrough oncology research into scalable partnerships and revenue streams.
“Data doesn’t create value until someone is willing to pay for the decision it enables,” says Sadaf Z. Malik, Head of Global Sales for Biobank and Biomarker Services at Crown Bioscience. “AI often falls short because it is not anchored in decision-making capacity.” Without this focus, even the most sophisticated models fail to drive the commercial momentum that matters.
Trust, Context, and Actionable Intelligence
Three critical gaps continue to constrain AI’s commercial potential in life sciences. First, models are frequently trained on clean, idealized datasets that bear little resemblance to the fragmented, biased, and noisy real-world data encountered in drug development. Second, outputs often lack the practical relevance needed to integrate into clinical or development workflows. Third, there is rarely a clear connection between insights and the budget justification or commercial decisions that drive revenue.
These challenges all trace back to a fundamental absence of context. “Without pre-analytical context, a dataset is simply noise,” explains Sadaf. “A model developed without that context remains nothing more than a hypothesis.”
For AI to move from experimentation to commercialization, two questions must be answered with clarity. Can the output be traced, explained, and defended? And would a pharmaceutical or diagnostic partner trust it enough to act on it, particularly when the stakes involve clinical trials or multimillion-dollar development programs?
Trust is the ultimate bridge between scientific insight and revenue growth. “If a pharma team isn’t willing to bet a trial decision on it, the AI has no commercial value. It’s that straightforward,” Sadaf notes. This emphasis on explainability and trust strengthens revenue pipelines, builds credible deal flow, and ensures oncology data translates into outcomes that withstand scrutiny from both scientific and commercial stakeholders.
Transforming Fragmented Data into Differentiated Value
The ability to derive meaning from complex, multimodal datasets represents one of the greatest opportunities in biotech today. Through what Sadaf calls “AI stitching”, the intelligent standardization, harmonization, and layering of disparate data sources, organizations can generate cross-cohort insights that are difficult for competitors to replicate.
This approach shifts the business model from selling raw samples or standalone services to offering integrated biobank solutions that deliver actionable intelligence. “Anyone can buy data,” Sadaf observes. “Very few know how to connect it in a way that truly drives decisions.”
By aligning scientific depth with commercial priorities, companies enhance pricing power, accelerate biomarker monetization, and build stronger oncology partnerships grounded in insights that directly inform development strategies and clinical go/no-go decisions.
Regulatory Readiness as a Competitive Advantage
As regulators place greater scrutiny on AI-generated data in clinical trials, proactive preparation is no longer optional. It is a strategic imperative. Reactive approaches risk delivering solutions that fail to meet FDA expectations.
“Preparation starts with embedding validation requirements, explainability, traceability, and reproducibility into your processes from the outset,” Sadaf advises. “You cannot sell something to the FDA that hasn’t been built into your protocols with regulatory context in mind.”
True cross-functional alignment across scientific, operational, and commercial teams ensures AI outputs meet regulatory standards while remaining commercially viable. Pharmaceutical partners are not investing in AI technology for its own sake. They are investing in confidence rooted in trusted data, rigorous validation, and a direct line from insight to measurable outcome.
From Services to Platforms in the Next Phase of Growth
The biotech industry is undergoing a structural evolution, moving away from transactional service models toward scalable, end-to-end platforms. Customers are no longer seeking quick fixes. They demand comprehensive solutions to their most pressing development challenges.
“What people are interested in isn’t a one-off transaction. They’re looking for a solution to their overall problem,” says Sadaf. This shift requires organizations to prioritize larger strategic partnerships, differentiated datasets, and repeatable offerings that deliver sustained value.
In this environment, AI itself is no longer a sufficient differentiator. “What will set leaders apart is AI that delivers insights capable of changing what the customer does next,” Sadaf emphasizes. The winners will be those who connect data to decisive action, insight to measurable impact, and science to scalable revenue.
Closing the Gap Between Data and Deal
The future of AI in life sciences will not be defined by algorithmic sophistication alone. It will be determined by how effectively organizations bridge scientific excellence with commercial execution, align teams, embed context and trust, and ensure every insight supports decisions that drive revenue.
Sadaf’s perspective offers a clear roadmap: prioritize trust and context, build with regulatory foresight, and develop platforms that deliver end-to-end value. Above all, every dataset, model, and output must contribute to a decision that someone, somewhere, is willing to act and pay for.
Follow Sadaf Z. Malik on LinkedIn or visit her personal website for more insights.
